STOCK TITAN

Altimmune (ALT) director granted 48,800 stock options at $2.82 exercise price

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
4

Rhea-AI Filing Summary

Altimmune, Inc. director Philip Hodges received a grant of stock options as part of his non-employee director compensation. The award covers 48,800 options to buy common stock at an exercise price of $2.82 per share, expiring on May 1, 2036.

The 48,800 underlying shares become vested and exercisable in substantially equal monthly installments over the 12 months following May 1, 2026, as long as Hodges continues to serve the company through each vesting date. This is a compensation-related award rather than an open-market purchase or sale.

Positive

  • None.

Negative

  • None.
Insider Hodges Philip
Role null
Type Security Shares Price Value
Grant/Award Stock Options (option to buy) 48,800 $0.00 --
Holdings After Transaction: Stock Options (option to buy) — 48,800 shares (Direct, null)
Footnotes (1)
  1. The options were granted pursuant to the Company's non-employee director compensation policy. The shares underlying the option become vested and exercisable in substantially equal monthly installments over the 12 months following May 1, 2026, subject to the reporting person's continued service through the applicable vesting date.
Options granted 48,800 options Stock options to buy Altimmune common stock granted to director
Exercise price $2.82 per share Conversion or exercise price of granted options
Expiration date May 1, 2036 Option term for director grant
Underlying shares 48,800 shares Common stock underlying stock option award
Vesting schedule 12 monthly installments Vests over 12 months following May 1, 2026
Post-transaction option holdings (this grant) 48,800 options Total options following transaction for this award
non-employee director compensation policy financial
"The options were granted pursuant to the Company's non-employee director compensation policy."
stock options financial
"Stock Options (option to buy)"
Stock options are agreements that give a person the right to buy or sell a company's stock at a specific price within a certain time frame. They are often used as a reward or incentive, similar to a coupon that can be used later if the stock price rises, allowing the holder to make a profit.
vested and exercisable financial
"The shares underlying the option become vested and exercisable in substantially equal monthly installments"
underlying security financial
"underlying_security_title": "Common Stock, par value $0.0001""
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Hodges Philip

(Last)(First)(Middle)
910 CLOPPER ROAD
SUITE 201S

(Street)
GAITHERSBURG MARYLAND 20878

(City)(State)(Zip)

UNITED STATES

(Country)
2. Issuer Name and Ticker or Trading Symbol
Altimmune, Inc. [ ALT ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
XDirector10% Owner
Officer (give title below)Other (specify below)
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
05/01/2026
6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Stock Options (option to buy)(1)$2.8205/01/2026A48,800 (2)05/01/2036Common Stock, par value $0.000148,800$048,800D
Explanation of Responses:
1. The options were granted pursuant to the Company's non-employee director compensation policy.
2. The shares underlying the option become vested and exercisable in substantially equal monthly installments over the 12 months following May 1, 2026, subject to the reporting person's continued service through the applicable vesting date.
/s/ Gregory Weaver, as Attorney-in-Fact05/01/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What insider transaction did Altimmune (ALT) director Philip Hodges report?

Philip Hodges reported receiving a grant of stock options for 48,800 shares of Altimmune common stock. The options were awarded as part of the company’s non-employee director compensation policy and represent a compensation grant, not an open-market stock purchase or sale.

How many Altimmune (ALT) shares are covered by Hodges’ new stock options?

The option grant covers 48,800 shares of Altimmune common stock. These shares are issuable upon exercise of the options, which vest in substantially equal monthly installments over 12 months following May 1, 2026, subject to continued service on each vesting date.

What is the exercise price and expiration date of Philip Hodges’ Altimmune options?

The options have an exercise price of $2.82 per share and expire on May 1, 2036. This means Hodges can, once vested, buy Altimmune common stock at $2.82 per share any time before the options expire, subject to plan and agreement terms.

How do Philip Hodges’ Altimmune options vest over time?

The 48,800 options vest and become exercisable in substantially equal monthly installments over the 12 months following May 1, 2026. Vesting is contingent on Hodges’ continued service with Altimmune through each applicable vesting date, aligning compensation with ongoing board service.

Is Hodges’ Form 4 transaction a market buy or sell of Altimmune (ALT) shares?

No, the Form 4 reflects a grant of stock options, not a market trade. The transaction is classified as a grant or award acquisition, providing Hodges with the right to purchase shares in the future, rather than an immediate purchase or sale in the open market.